Walleye Capital
UBX

Walleye Capital’s Unity Biotechnology UBX Stock Holding History

Walleye Capital’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,288
Closed -$37K – 2732
2022
Q1 		$37K Sell
3,288
-2,149
-40% -$24.1K ﹤0.01% 1870
2021
Q4 		$79K Buy
5,437
+4,176
+331% +$91.3K ﹤0.01% 1728
2021
Q3 		$38 Sell
1,261
-3,324
-72% -$117K ﹤0.01% 1421
2021
Q2 		$213 Buy
+4,585
New +$221K 0.01% 1050
2020
Q4 		– Sell
-4,610
Closed -$159K – 1110
2020
Q3 		$159K Buy
+4,610
New +$292K 0.02% 655
2020
Q1 		– Sell
-1,704
Closed -$123K – 1681
2019
Q4 		$123K Buy
+1,704
New +$120K 0.01% 1307

Other funds holding UBX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's UBX Position: Q2 2022 in Review

Walleye Capital sold out of Unity Biotechnology (UBX) in Q2 2022, closing a stake of 3,288 shares — an estimated $37K sold.

Walleye Capital first reported a position in UBX in Q4 2019 and held it in 6 quarters. The position peaked at $159K in Q3 2020. 65 funds tracked by Wall St. Rank hold UBX as of Q2 2022.

  • Walleye Capital reported no remaining Unity Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 3,288 Unity Biotechnology shares in Q2 2022, an estimated $37K.
  • Walleye Capital first reported a position in Unity Biotechnology in Q4 2019 and held it in 6 quarters.
  • Walleye Capital's Unity Biotechnology position peaked at $159K in Q3 2020.
  • 65 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.